Medicine and Dentistry
Prostate Cancer
100%
Positron Emission Tomography-Computed Tomography
99%
Diffuse Large B-Cell Lymphoma
73%
Overall Survival
67%
Malignant Neoplasm
64%
Bone Metastasis
60%
Gallium 68
60%
Systematic Review
54%
Cohort Analysis
53%
Bone Scintigraphy
53%
Neoplasm
52%
Pancreas Cancer
48%
Diseases
47%
Biological Marker
47%
Cancer
37%
Diagnosis
33%
Fluorine-18
31%
Hazard Ratio
30%
Non Small Cell Lung Cancer
28%
Colorectal Cancer
26%
Acute Myeloid Leukemia
25%
Metastatic Carcinoma
24%
Clinical Trial
23%
Immune Checkpoint Inhibitor
22%
Minimal Residual Disease
22%
Positron Emission Tomography
21%
Biopsy
21%
Multiple Myeloma
21%
Pancreas Adenocarcinoma
21%
Radiation Therapy
21%
Computer Assisted Tomography
21%
Lung Cancer
19%
Prostate Specific Membrane Antigen
19%
Progression Free Survival
17%
Hodgkin's Lymphoma
17%
Fluorodeoxyglucose F 18
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Venous Thromboembolism
16%
Gene Expression
16%
Positron Emission Tomography
16%
Non-Hodgkin Lymphoma
16%
B Cell
15%
Rituximab
15%
Prospective Study
14%
Quality of Life
14%
Promoter Region
14%
Cancer Risk
14%
Diagnostic Accuracy
14%
Cancer Staging
14%
Oncology
14%
Pleura Mesothelioma
14%
Proportional Hazards Model
14%
Personalized Medicine
13%
Rectum Cancer
13%
Randomized Controlled Trial
13%
Recurrent Disease
13%
Gemcitabine
13%
Prostatectomy
13%
Immunotherapy
13%
Drug Megadose
12%
Adjuvant Chemotherapy
12%
Recurrence Risk
12%
Circulating Tumor DNA
12%
Biochemical Recurrence
12%
Prognostic Factor
12%
Cancer Therapy
11%
Magnetic Resonance Imaging
11%
Low Drug Dose
11%
Vincristine
11%
microRNA
11%
Thyroid Gland
11%
Krukenberg Tumor
11%
Treatment Response
11%
Follicular Lymphoma
11%
International Prognostic Index
10%
Cell-Free DNA
10%
Cancer Treatment
10%
Population
9%
Incidental Finding
9%
Neuroendocrine Tumor
9%
Prevalence
9%
Mortality
9%
Irreversible Electroporation
9%
Ovarian Cancer
9%
Rheumatoid Arthritis
9%
Single Photon Emission Computed Tomography-Computed Tomography
9%
Second Cancer
9%
Myeloma
9%
Symptom
9%
Combination Chemotherapy
9%
Fluorodeoxyglucose
8%
BRCA1
8%
Cyclophosphamide
8%
Hematological Cancer
8%
Supportive Care
8%
Lymph Node
8%
Hematologic Malignancy
8%
Psychoactive Drug
8%
Androgen Deprivation Therapy
8%
Surgery
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
51%
Overall Survival
49%
Malignant Neoplasm
42%
Prostate Cancer
36%
Cohort Study
36%
Neoplasm
33%
Disease
32%
Biological Marker
29%
Pancreas Cancer
28%
Pancreas Adenocarcinoma
28%
Diffuse Large B Cell Lymphoma
26%
Acute Myeloid Leukemia
25%
Non Small Cell Lung Cancer
24%
Colorectal Cancer
23%
Immune Checkpoint Inhibitor
19%
Progression Free Survival
16%
Bone Metastasis
16%
Lung Cancer
14%
Pleura Mesothelioma
12%
Minimal Residual Disease
12%
Recurrent Disease
12%
Remission
12%
Clinical Trial
11%
Psychotropic Agent
11%
Vincristine
11%
Prostate Specific Membrane Antigen
10%
Fluorine 18
9%
Rectum Cancer
9%
Cancer Staging
9%
Prevalence
8%
Secreted Frizzled Related Protein 1
8%
Recurrence Risk
8%
Follicular Lymphoma
8%
Solid Malignant Neoplasm
8%
Adverse Event
8%
Gemcitabine
7%
Programmed Death 1 Ligand 1
7%
Hematologic Malignancy
7%
Immunotherapy
7%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
7%
Randomized Controlled Trial
7%
Cancer Recurrence
7%
Myelodysplastic Syndrome
7%
Patient Registry
7%
Nonhodgkin Lymphoma
6%
Castration Resistant Prostate Cancer
6%
Circulating Tumor DNA
6%
Second Cancer
6%
Telomerase
6%
Gallium 68
6%
High Dose Chemotherapy
6%
Neuroendocrine Tumor
6%
Venetoclax
6%
Sodium Fluoride
6%
Chemoradiation Therapy
6%
microRNA 155
6%
Hodgkin Disease
6%
Esophagus Cancer
6%
Rituximab
6%
Multiple Myeloma
5%
Monotherapy
5%
Drug Resistance
5%
Anticarcinogen
5%
Glucocorticoid
5%
Comorbidity
5%
Nivolumab
5%
microRNA
5%
Keyphrases
National Cohort Study
29%
Denmark
26%
Lymphoma
13%
Lymphoma Patients
12%
Colorectal Cancer
10%
Rheumatoid Arthritis
9%
Risk Factors
8%
Confidence Interval
8%
Pancreatic Adenocarcinoma
8%
Population-based
7%
Prostate Cancer
7%
Hazard Ratio
6%
SFRP1
6%
PSMA PET-CT
6%
Newly Diagnosed
6%
Gemcitabine
6%
Danish Registers
6%
Register Study
6%
Pancreatic Ductal Adenocarcinoma
6%
Local Recurrence Rate
6%
Recurrent Prostate Cancer
6%
Ga-PSMA
6%
Atrial Fibrillation
6%
Patient Cohort
6%
Fibroblast Activation Protein Inhibitor
6%
18F-sodium Fluoride PET
6%
Second Primary Malignancy
6%
Eosinophilic Esophagitis
6%
Polyautoimmunity
6%
New-onset Diabetes
6%
Systemic Anti-cancer Treatment
6%
Reproduction Pattern
6%
Oncologic Emergency
6%
Matched Cohort Study
6%
Exhaled Breath Condensate
6%
Bone Scan Index
6%
Promoter Methylation
6%
Curative Treatment
6%
Pancreatic Cancer
6%
Overall Survival
6%
Bone Scintigraphy
5%
Follicular Lymphoma
5%
Danish National Patient Registry
5%
Odds Ratio
5%
Diffuse Large B-cell Lymphoma (DLBCL)
5%